Evolus, Inc. (EOLS)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation
Ask a question about Evolus, Inc. (EOLS)
Company Performance

Current Price

as of Oct 16, 2024

$17.45

P/E Ratio

N/A

Market Cap

$1.1B

Description

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Metrics

Overview

  • HQNewport Beach, CA
  • SectorHealth Technology
  • IndustryPharmaceuticals: Major
  • TickerEOLS
  • Price$17.45+4.49%

Trading Information

  • Market Cap$1.10B
  • Float86.31%
  • Average Daily Volume (1m)645,284
  • Average Daily Volume (3m)579,188
  • EPS-$0.91

Company

  • Revenue$237.26M
  • Rev Growth (1yr)35.59%
  • Net Income-$11.35M
  • Gross Margin69.36%
  • EBITDA Margin-6.98%
  • EBITDA-$4.67M
  • EV$713.64M
  • EV/Revenue3.01
  • P/EN/A
  • P/S4.61
  • P/B56.97
Documents
SEC Filings
8-K (2024-07-31)
8-K (2024-07-01)
8-K (2024-06-11)
8-K (2024-05-07)
8-K (2024-04-03)
8-K (2024-03-13)
8-K (2024-03-07)
8-K (2024-01-16)
8-K (2023-12-20)
8-K (2023-11-07)
8-K (2023-08-02)
8-K (2023-07-27)
8-K (2023-06-14)
8-K (2023-05-09)
8-K (2023-03-13)
8-K (2023-03-08)
8-K (2023-01-18)
10-Q (2024-07-31)
10-Q (2024-05-07)
10-Q (2023-11-07)
10-Q (2023-08-02)
10-Q (2023-05-09)
10-K (2024-03-07)
10-K (2023-03-08)
Earnings Calls
Earnings Report 2024Q2
Earnings Report 2024Q1
Earnings Report (2023-11-07)
Earnings Report (2023-08-02)
Factset Street Account
StreetAccount Earnings Call Q&A Summary: Evolus Q3 (2023-11-08T11:29:24Z)
Evolus reports Q3 GAAP EPS ($0.30) vs year-ago ($0.36) ($8.08, 0.00) (2023-11-07T21:49:56Z)
Evolus announces results from the Phase 2 clinical study evaluating the "extra-strength" 40U dose for extended duration of Jeuveau ($7.93, 0.00) (2023-11-06T13:46:59Z)
Factset
Factset Business Description